Purchase of an Illumina MiSeq i100 plus

The Food and Drug Administration is forecasting the purchase of an Illumina MiSeq i100 plus sequencer to enhance its culture-independent pathogen identification program, specifically to enable rapid long-read sequencing for detecting pathogens in seafood and environmental samples. This equipment will support the development of real-time screening capabilities crucial for identifying harmful microbes directly from field-collected samples, improving response times and food safety outcomes. The acquisition is aligned with the agency’s mission to safeguard public health through advanced molecular surveillance technologies. The solicitation is categorized under NAICS code 541990, indicating research and development in the physical, engineering, and life sciences. The point of contact for program inquiries is the Hfp Acquisition Liaison at hfpacquisitions@fda.hhs.gov, while the contracting officer position remains to be determined. The instrument’s deployment will occur under the agency’s operational scope with no specific location detailed in the forecast, and the opportunity was posted on May 25, 2026, with no set-asides or procurement restrictions indicated.